You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Antiviral Drugs for Lassa Fever Virus

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Hemorrhagic fever viruses are of serious worldwide health concern as well as potential biological weapons. Lassa fever virus in particular annually infects several hundred thousand individuals in West Africa, and the export of this pathogen outside of this region, either intentionally or unintentionally, presents a serious risk to the developed countries of the ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Small Molecule Inhibitors of Smallpox Virus Replication

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Concern over the use of variola virus as a biological weapon has prompted interest in development of small molecule therapeutics for smallpox. Variola virus is highly transmissible and causes severe disease with high mortality rates. Currently, there is no FDA-approved drug for prevention or treatment of smallpox. The overall goal of this smallpox antiviral pro ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  3. A Single-Cell Proteomic instrument for Predictive Product Quality Check in Autologous CAR-T Immunotherapies

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    While CAR-T therapies have advanced in the clinic, there are still two specific issues using these breakthrough therapies for blood cancers: Durable responses in patients are only at 30-50% and Cytokine Release Syndrome occurs in 60-90% of treated patients. These limitations, for a drug that costs as much as $500,000, may cost an additional $250,000+ for treating adverse events leading to caution ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT

    SBC: Elex Biotech, Inc            Topic: NHLBI

    PROJECT SUMMARY The goal of this project is to complete the preclinical development of Elex Biotechandapos;s novel compounds that target and treat the underlying molecular cause of catecholaminergic polymorphic ventricular tachycardia (CPVT) CPVT. There are no FDA-approved treatments for CPVT, a rare genetic disorder affecting 1/10,000 individuals, with typical onset in children 7-9 years of age a ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses

    SBC: HAWAII BIOTECH, INC.            Topic: NIAID

    Project Summary/AbstractThe NIH/NIAID 2017 Strategic Plan is specifically directed at promoting research that can provide solutions to mitigate the threat posed by emerging and re-emerging diseases. The tick-borne flavivirus (TBFV) group includes a number of important human pathogens that result in serious neurological or hemorrhagic diseases that are either Category B or C priority pathogens. The ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery

    SBC: BIOKIER, INC.            Topic: 200

    SUMMARY Glucose homeostasis and food intake are both regulated by gut hormones secreted from enteroendocrine L- cells in the lower gut following stimulation by nutrients. This process is impaired in diabetes but is restored with delivery of dietary nutrients such as amino acids and fatty acids to the lower gut, such as after gastric bypass surgery and during fermentation of carbohydrates in the co ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    Abstract Polychromatic flow cytometry (FC) is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells. Dyes used for FC typically exhibit broad fluorescent emission bands with full-width-at-half-maximum (fwhm) values of 50–80 nm. This limits the maximum number of dyes, and thus the nu ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Clinical Development a Therapeutic Agent for COPD

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: N/A

    Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases, including chronic pulmonary disease (COPD), asthma, cystic fibrosis, and bronchiectasis. Despite the obvious medical importance, there presently are no effective therapies to control excess mucus secretion in these diseases, and very few potential therapeutic targets. We discovered that a ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Improving Spatiotemporal Precision in Noninvasive Electrical Neuromodulation

    SBC: Brain Electrophysiology Laboratory Company, LLC            Topic: 101

    This application describes the commercialization of the Geodesic Transcranial Electrical Neuromodulation (GTEN) technology to achieve noninvasive neuromodulation with improved spatiotemporal precision. The GTEN system enables both EEG source analysis and configurable electrical neuromodulation with the 256 electrodes of the Geodesic Sensor Net. Now in beta release to selected research customers, t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a New Carbohydrate-based Anticoagulant Drug

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: NHLBI

    Low molecular weight heparins (LMWHs) are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US. This crisis revealed the vulnerability of the LMWH supply chain. LMWHs are complex mixtures, having average molecular masses of 3500-6000 Daltons, corresponding to ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government